Sumitomo Dainippon Pharma Co Ltd's Fiscal Year is From April To March.
The item "Price-To-Cashflow-Ratio" stands at 20.96 as of 09/30/2025, the highest value since 06/30/2023.
As of the end of Sumitomo Dainippon Pharma Co Ltd's second quarter, the item "Price To Cashflow Ratio" stands at 20.96. This represents an increase of 119.31 percent compared to it's value at the end of it's first quarter .
Regarding the One-Year-Change of the series, the current value constitutes an increase of 24.90 compared to the value the year prior.
The Serie's long term average value is 3.85. It's latest available value, on 09/30/2025, is 17.11 higher, compared to it's long term average value.
The Serie's change from it's minimum value, on 12/31/2024, to it's latest available value, on 09/30/2025, is +60.41 .
The Serie's change from it's maximum value, on 03/31/2023, to it's latest available value, on 09/30/2025, is -5.86 .
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Price To Cashflow Ratio | 905,699,262,464.00 |
![]() | Johnson & Johnson - Price To Cashflow Ratio | 486,508,953,600.00 |
![]() | AbbVie Inc - Price To Cashflow Ratio | 399,570,305,024.00 |
![]() | Roche Holding AG - Price To Cashflow Ratio | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Price To Cashflow Ratio | 280,205,508,085.11 |